The cardioprotective role of beta-blockers in patients with diabetes mellitus
| Autor: | Martin J Landray, M. J. Kendall, V Toescu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Adrenergic beta-Antagonists Coronary Disease Sudden death law.invention Diabetes Complications Randomized controlled trial law Diabetes mellitus Good evidence medicine Humans Pharmacology (medical) In patient Cardioprotective Agent Prospective Studies Practice Patterns Physicians' Intensive care medicine Adverse effect Cardiovascular mortality Pharmacology business.industry medicine.disease Surgery Death Sudden Cardiac business |
| Popis: | This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|